Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

CRANBURY, N.J., June 01, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. FOLD announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 12, 2018 at 2:00 p.m. P.T.

A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days. 

About Amicus Therapeutics
Amicus Therapeutics FOLD is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is migalastat, an oral precision medicine for people living with Fabry disease who have amenable genetic mutations. Migalastat is currently approved under the trade name Galafold™ in the European Union, with additional approvals granted and pending in several geographies. The lead biologics program in the Amicus pipeline is AT-GAA, a novel, late-stage, potential best-in-class treatment paradigm for Pompe disease. The Company is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. 

CONTACTS:

Investors/Media:
Amicus Therapeutics
Sara Pellegrino, IRC
Vice President, Investor Relations & Corporate Communications
spellegrino@amicusrx.com
(609) 662-5044

Media:
Pure Communications
Jennifer Paganelli
jpaganelli@purecommunications.com 
(347) 658-8290

FOLD–G